A5026637170- Antifungal resistance and susceptibility
- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Fungal Infections and Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Respiratory Support and Mechanisms
- Tracheal and airway disorders
- Pleural and Pulmonary Diseases
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Sarcoidosis and Beryllium Toxicity Research
- Airway Management and Intubation Techniques
- Cystic Fibrosis Research Advances
- Intensive Care Unit Cognitive Disorders
- Mycobacterium research and diagnosis
- Medical Imaging and Pathology Studies
- Tuberculosis Research and Epidemiology
- Long-Term Effects of COVID-19
- Infectious Diseases and Mycology
- Neonatal Respiratory Health Research
- COVID-19 Clinical Research Studies
- Lung Cancer Research Studies
- Cardiac Arrest and Resuscitation
Post Graduate Institute of Medical Education and Research
2016-2025
Pulmonary Associates
2016-2024
Creative Commons
2022-2023
Institute of Medical Sciences
2023
SRM Institute of Science and Technology
2023
Christie's
2020-2022
Medanta The Medicity
2021
Kokilaben Dhirubhai Ambani Hospital
2021
Chandigarh University
2020
Creative Research Enterprises (United States)
2018
During September-December 2020, we conducted a multicenter retrospective study across India to evaluate epidemiology and outcomes among cases of coronavirus disease (COVID-19)-associated mucormycosis (CAM). Among 287 patients, 187 (65.2%) had CAM; CAM prevalence was 0.27% hospitalized COVID-19 patients. We noted 2.1-fold rise in during the period compared with 2019. Uncontrolled diabetes mellitus most common underlying non-CAM only 32.6% COVID-19-related hypoxemia improper glucocorticoid use...
Reports are increasing on the emergence of COVID-19-associated mucormycosis (CAM) globally, driven particularly by low- and middle-income countries. The recent unprecedented surge CAM in India has drawn worldwide attention. More than 28,252 cases counted is first country where been declared a notifiable disease. However, misconception management, diagnosing treating this infection continue to occur. Thus, European Confederation Medical Mycology (ECMM) International Society for Human Animal...
Background The International Society for Human and Animal Mycology (ISHAM) working group proposed recommendations managing allergic bronchopulmonary aspergillosis (ABPA) a decade ago. There is need to update these due advances in diagnostics therapeutics. Methods An international expert was convened develop guidelines ABPA (caused by Aspergillus spp.) mycosis (ABPM; caused fungi other than adults children using modified Delphi method (two online rounds one in-person meeting). We defined...
Contents: Executive Summary Introduction Methodology Definition, Epidemiology and Risk Factors Diagnosis of Asthma Management Stable Acute Exacerbations Miscellaneous Issues in EXECUTIVE SUMMARY is defined as a chronic inflammatory disorder the airways which manifests itself recurrent episodes wheezing, breathlessness, chest tightness cough. It characterized by bronchial hyper-responsiveness variable airflow obstruction, that often reversible either spontaneously or with treatment. The...
Pandemics like the coronavirus disease (COVID)-19 can cause a significant strain on healthcare system. Healthcare organizations must be ready with their contingency plans for managing many patients contagious infectious disease. Ideally, every large hospital should have facility that function as high-level isolation unit. An unit ensures staff and are equipped to deal outbreaks. Unfortunately, such facilities do not exist in several hospitals, especially resource-limited settings. In...
Whether a combination of glucocorticoid and antifungal triazole is superior to alone in reducing exacerbations patients with allergic bronchopulmonary aspergillosis (ABPA) remains unknown. We aimed compare the efficacy safety prednisolone-itraconazole versus prednisolone monotherapy ABPA.We randomised subjects treatment-naïve acute-stage ABPA complicating asthma receive either (4 months) or itraconazole 6 months, respectively). The primary outcomes were exacerbation rates at 12 months...
Background Current guidelines recommend 20–40 mg·day −1 of oral prednisolone for treating pulmonary sarcoidosis. Whether the higher dose (40 ) can improve outcomes remains unknown. Methods We conducted an investigator-initiated, single-centre, open-label, parallel-group, randomised controlled trial ( ClinicalTrials.gov identifier NCT03265405 ). Consecutive subjects with sarcoidosis were (1:1) to receive either high-dose initial dose) or low-dose (20 prednisolone, tapered over 6 months. The...
Abstract Background The role of nebulized amphotericin B (NAB) in managing pulmonary mucormycosis (PM) is unknown. Methods In this open‐label trial, we randomized PM subjects to receive either intravenous liposomal (control arm, 3–5 mg/kg/day) alone or along with deoxycholate (NAB, 10 mg twice a day, every alternate day). primary outcomes were: (1) overall response (‘success’ [complete partial response] ‘failure’ [stable disease, progressive death]) at 6 weeks; and (2) the proportion adverse...